BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31876116)

  • 21. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias.
    Karp JE; Ricklis RM; Balakrishnan K; Briel J; Greer J; Gore SD; Smith BD; McDevitt MA; Carraway H; Levis MJ; Gandhi V
    Blood; 2007 Sep; 110(6):1762-9. PubMed ID: 17562873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.
    Srivastava S; Jones D; Wood LL; Schwartz JE; Nelson RP; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Robertson MJ; Farag SS
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):987-94. PubMed ID: 20965266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
    Steinherz PG; Shukla N; Kobos R; Steinherz L
    Pediatr Blood Cancer; 2010 May; 54(5):687-93. PubMed ID: 20205253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia.
    Stumpel DJ; Schneider P; Pieters R; Stam RW
    Eur J Cancer; 2015 Sep; 51(14):2008-21. PubMed ID: 26188848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The first Japanese biobank of patient-derived pediatric acute lymphoblastic leukemia xenograft models.
    Tanaka K; Kato I; Dobashi Y; Imai JI; Mikami T; Kubota H; Ueno H; Ito M; Ogawa S; Nakahata T; Takita J; Toyoda H; Ogawa C; Adachi S; Watanabe S; Goto H
    Cancer Sci; 2022 Nov; 113(11):3814-3825. PubMed ID: 35879192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
    Jeha S; Gaynon PS; Razzouk BI; Franklin J; Kadota R; Shen V; Luchtman-Jones L; Rytting M; Bomgaars LR; Rheingold S; Ritchey K; Albano E; Arceci RJ; Goldman S; Griffin T; Altman A; Gordon B; Steinherz L; Weitman S; Steinherz P
    J Clin Oncol; 2006 Apr; 24(12):1917-23. PubMed ID: 16622268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan.
    Koh K; Ogawa C; Okamoto Y; Kudo K; Inagaki J; Morimoto T; Mizukami H; Ecstein-Fraisse E; Kikuta A
    Int J Hematol; 2016 Aug; 104(2):245-55. PubMed ID: 27086352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia.
    McGregor BA; Brown AW; Osswald MB; Savona MR
    Am J Hematol; 2009 Apr; 84(4):228-30. PubMed ID: 19260120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo activity of the dual PI3Kδ and PI3Kγ inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenografts.
    Randall J; Evans K; Watts B; Smith CM; Hughes K; Earley EJ; Erickson SW; Pachter JA; Teicher BA; Smith MA; Lock RB
    Pediatr Blood Cancer; 2023 Aug; 70(8):e30398. PubMed ID: 37140091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Examining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemia.
    Alruwetei AM; Bendak K; Yadav BD; Carol H; Evans K; Mayoh C; Sutton R; Marshall GM; Lock RB
    Br J Cancer; 2020 Sep; 123(5):742-751. PubMed ID: 32536690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of clofarabine, cyclophosphamide, and etoposide for relapsed or refractory childhood and adolescent acute myeloid leukemia.
    Messinger Y; Boklan J; Goldberg J; DuBois SG; Oesterheld J; Abla O; Martin A; Weinstein J; Hijiya N
    Pediatr Hematol Oncol; 2017 May; 34(4):187-198. PubMed ID: 29039989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.
    Carol H; Szymanska B; Evans K; Boehm I; Houghton PJ; Smith MA; Lock RB
    Clin Cancer Res; 2013 Apr; 19(7):1795-805. PubMed ID: 23426279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clofarabine and nelarabine: two new purine nucleoside analogs.
    Gandhi V; Plunkett W
    Curr Opin Oncol; 2006 Nov; 18(6):584-90. PubMed ID: 16988579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clofarabine-based salvage chemotherapy for relapsed or refractory acute leukemia before allogeneic stem cell transplantation: results from a case series.
    Grigoleit GU; Kapp M; Tan SM; Unzicker C; Einsele H; Mielke S; Topp MS; Stuhler G
    Leuk Lymphoma; 2009 Dec; 50(12):2071-4. PubMed ID: 19886845
    [No Abstract]   [Full Text] [Related]  

  • 36. Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts.
    Jones L; McCalmont H; Evans K; Mayoh C; Kurmasheva RT; Billups CA; Houghton PJ; Smith MA; Lock RB
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27765. PubMed ID: 31012549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I/II study of clofarabine, etoposide, and mitoxantrone in patients with refractory or relapsed acute leukemia.
    Abbi KK; Rybka W; Ehmann WC; Claxton DF
    Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):41-6. PubMed ID: 25085441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.
    van Eijkelenburg NKA; Rasche M; Ghazaly E; Dworzak MN; Klingebiel T; Rossig C; Leverger G; Stary J; De Bont ESJM; Chitu DA; Bertrand Y; Brethon B; Strahm B; van der Sluis IM; Kaspers GJL; Reinhardt D; Zwaan CM
    Haematologica; 2018 Sep; 103(9):1484-1492. PubMed ID: 29773602
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The combination of clofarabine and cytarabine in pediatric relapsed acute lymphoblastic leukemia: a case report.
    Gidwani P; Ramesh KH; Liu Y; Kolb EA
    Chemotherapy; 2008; 54(2):120-4. PubMed ID: 18303261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias.
    Abd Elmoneim A; Gore L; Ricklis RM; Boklan J; Cooper T; Narendran A; Rolla K; Scott T; Arceci RJ
    Pediatr Blood Cancer; 2012 Dec; 59(7):1252-8. PubMed ID: 22887831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.